Study guide

19.1 Dosage Form Design & the Biopharmaceutics Classification System

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

19.1 Dosage Form Design & the Biopharmaceutics Classification System

Key Takeaways Explain This Topic AI

Dosage form choice (solid, liquid, semisolid, parenteral, transdermal, inhalation, rectal, implant) directly controls onset, extent of bioavailability, and stability; modified-release tablets (enteric-coated, sustained/extended-release) alter the release site or rate to protect the drug or smooth plasma concentrations.

The Biopharmaceutics Classification System (BCS) categorises drugs by solubility and permeability: Class I (high/high, e.g. metoprolol), Class II (low solubility/high permeability, dissolution-rate-limited, e.g. ibuprofen, atorvastatin), Class III (high solubility/low permeability, permeability-limited, e.g. atenolol), and Class IV (low/low, problematic, e.g. furosemide).

Oral absorption proceeds in sequence: disintegration of the dosage form, then dissolution of drug particles into gastrointestinal fluid, then permeation across the enterocyte membrane — the slowest step governs overall absorption rate.

Bioavailability is the fraction of administered dose reaching the systemic circulation unchanged; hepatic first-pass metabolism markedly reduces oral bioavailability of high-extraction drugs such as propranolol and morphine, necessitating non-oral routes when systemic effect is required.

BCS solubility is dose-dependent (a drug is 'highly soluble' if its highest therapeutic dose dissolves in 250 mL across pH 1-7.5) and permeability correlates with the fraction absorbed in humans.

Last updated: August 2026

Dosage Forms and Why Route Choice Matters

A dosage form is the physical vehicle that delivers a drug to the body in a stable, measurable, and clinically appropriate way. The same drug substance can be formulated into several dosage forms, and the choice of form plus route of administration governs three things the exam tests repeatedly: onset of action , extent of bioavailability , and chemical stability .

Solid oral dosage forms

Tablets and capsules are the most common solid oral forms because they are convenient, dose-accurate, and stable. Modified-release tablets manipulate where or how fast the drug releases:

Enteric-coated tablets (e.g. aspirin low-dose, omeprazole) resist gastric acid and dissolve in the higher pH of the small intestine, protecting either the drug from acid degradation or the stomach mucosa from irritation.

Sustained-release / extended-release formulations (e.g. metoprolol succinate ER, morphine SR) release drug slowly to maintain therapeutic plasma concentrations over 12-24 hours, smoothing peaks that cause side effects and troughs that allow symptom breakthrough.

Liquid dosage forms

Solutions — drug fully dissolved; fastest oral onset among liquids because no dissolution step is required.

Suspensions — insoluble drug dispersed in a liquid vehicle; must be shaken before dosing and may sediment on storage.

Emulsions — two immiscible phases stabilised by an emulsifying agent; prone to creaming and cracking.

Syrups — concentrated sucrose solutions that improve taste and act as a mild preservative.

Elixirs — hydroalcoholic solutions (e.g. paracetamol elixir); alcohol co-solvent improves solubility of poorly water-soluble drugs.

Tinctures — alcoholic extracts of botanical or drug material.

Semisolid, parenteral, and specialised forms

Category Examples Key point

Semisolid Creams (o/w), ointments (w/o or oleaginous), gels Creams are water-washable; ointments are more occlusive and enhance penetration

Parenteral IV, IM, SC, intrathecal IV bypasses absorption entirely (F = 1); IM/SC depend on local blood flow

Transdermal patches GTN, fentanyl, oestradiol Provide steady systemic input over hours to days; bypass first-pass metabolism

Inhalers Salbutamol MDI, budesonide DPI Deliver drug directly to airways; low systemic dose minimises side effects

  • Suppositories Paracetamol, bisacodyl Useful when oral route is unavailable (vomiting, unconsciousness)
  • Implants Contraceptive etonogestrel implant Provide weeks to years of sustained release

Exam trap: Enteric-coated and sustained-release tablets must never be crushed or split — doing so destroys the modified-release mechanism, causing either gastric irritation (enteric coat lost) or dose dumping with potential toxicity (sustained-release matrix broken). If a patient cannot swallow intact, an alternative formulation (liquid, dispersible, or IV) must be chosen.

The Biopharmaceutics Classification System (BCS)

The BCS is a regulatory framework that classifies oral drug substances by two properties: solubility and intestinal permeability . A drug is considered highly soluble when its highest therapeutic strength dose dissolves in 250 mL of aqueous media across the pH range 1-7.5 at 37 °C. High permeability generally means ≥90% absorbed in humans. The four classes predict the rate-limiting step for oral absorption:

  • BCS Class Solubility Permeability Examples Rate-limiting step
  • I High High Metoprolol, propranolol, theophylline Gastric emptying (fast, complete absorption)

II Low High Ibuprofen, felodipine, atorvastatin, ketoconazole Dissolution rate — improving solubility boosts absorption

  • III High Low Atenolol, ranitidine, cimetidine Permeability — improving solubility alone does not help
  • IV Low Low Furosemide, taxol (paclitaxel) Both steps problematic; often poorly and variably absorbed

Why this matters clinically and on the exam:

Class II drugs benefit from formulation strategies that increase dissolution rate — micronisation (reducing particle size to increase surface area), salt formation , or amorphous solid dispersions .

Class III drugs are already soluble, so making them smaller or saltier does not materially improve absorption; instead, absorption enhancers or prodrug approaches that increase permeability are needed.

Class I and III drugs (highly soluble) can use dissolution testing as a bioequivalence surrogate in lieu of full in-vivo pharmacokinetic studies — the basis of the FDA biowaiver.

Biopharmaceutics: From Tablet to Systemic Circulation

Biopharmaceutics studies how the physicochemical properties of the drug and the dosage form, together with the route of administration, determine the rate and extent of drug absorption. For an immediate-release oral tablet, absorption proceeds through three sequential steps:

Disintegration — the tablet breaks apart into primary drug particles under the action of disintegrants and gastrointestinal motility.

Dissolution — drug particles dissolve into the gastrointestinal fluid; governed by the Noyes-Whitney equation (covered in section 19.2).

Absorption — dissolved drug crosses the enterocyte membrane into the portal blood.

The slowest of these three steps is the rate-limiting step . For Class II drugs, dissolution is slowest; for Class III drugs, permeation across the membrane is slowest.

Bioavailability (F) is the fraction of the administered dose that reaches the systemic circulation in an unchanged, active form. For an IV dose, F = 1 (100%) by definition because the drug is placed directly into the bloodstream. For oral dosing, F is reduced by two factors: incomplete absorption across the gut wall and first-pass (presystemic) metabolism in the liver and gut wall. Drugs with high hepatic extraction ratios — propranolol , morphine , glyceryl trinitrate , levodopa — have markedly reduced oral bioavailability and may require much larger oral doses or non-oral routes (sublingual, transdermal, IV) to achieve a systemic effect.

Worked example: Morphine has an oral bioavailability of roughly 25-30% due to extensive first-pass metabolism. To achieve equivalent systemic exposure, a 10 mg IV dose would require approximately 30-40 mg orally — a clinical fact the DHA exam may frame as a dosing-conversion question.